Buyer’s Guide
7 Best EDC Software Platforms for UK Clinical Trials in 2026
The seven best EDC software platforms to consider for United Kingdom (UK) clinical trials in 2026 are Clinion EDC, Viedoc, Medidata Rave EDC, Veeva Vault EDC, Castor EDC, Medrio EDC, and Oracle Clinical One. In addition to core EDC capabilities such as study setup, data management, reporting, and integrations, UK sponsors and CROs should evaluate these platforms for MHRA inspection readiness, ICH E6(R3) alignment, UK GDPR safeguards, and support for UK clinical trial operations.
The UK’s updated clinical trial regulations came into force on 28 April 2026, bringing changes to trial oversight, risk-proportionate approaches, and regulatory processes. Alongside ICH E6(R3) Good Clinical Practice expectations, these developments place greater emphasis on reliable clinical data, documented system controls, and inspection readiness.
For UK sponsors and CROs, choosing EDC software therefore means evaluating more than data capture features. Audit trails, system validation, protocol amendment management, UK GDPR safeguards, and support for multicentre studies are important considerations.
This guide compares seven EDC platforms to help UK clinical trial teams identify the right fit for their regulatory, operational, and data management needs.
Quick Comparison of the 7 Best EDC Platforms for UK Clinical Trials
Clinion EDC
Sponsors and CROs seeking AI-driven clinical data management
Viedoc
Medidata Rave EDC
Veeva Vault EDC
Castor EDC
Medrio EDC
Oracle Clinical One
How We Selected These EDC Platforms
We reviewed official product documentation, security and compliance disclosures, and independent user reviews on G2 and Capterra. Our comparison prioritises verified EDC capabilities, integrations, and suitability for UK clinical trials, including validation, auditability, and data protection.
These platforms are presented for comparison, not as a numerical ranking.
Detailed Reviews of the 7 Best EDC Software Platforms for UK Clinical Trials in 2026
The following reviews examine each platform’s core capabilities, distinguishing features, and suitability for UK clinical trials. They also highlight relevant regulatory and data protection considerations, helping sponsors and CROs assess which solution best fits their study requirements.
1. Clinion EDC
Clinion EDC combines codeless study configuration, AI-powered clinical data management, and connected eClinical applications. Teams can configure eCRFs, edit checks, and visit schedules using reusable libraries, while controlled mid-study amendments support changes to active trials.
Clinion’s AI capabilities include discrepancy detection, medical coding, CDASH mapping, and natural-language reporting. Its Agentic Assistant supports AI-driven workflows across Clinion’s eClinical ecosystem, including EDC, CTMS, RTSM, ePRO, eConsent, and eSource.
Key features
- Codeless study builds with reusable libraries and version-controlled amendments.
- AI-assisted data review, medical coding, CDASH mapping, and reporting.
- Agentic Assistant and integration across connected eClinical applications.
UK regulatory and data protection relevance
Clinion documents support for ICH GCP, FDA 21 CFR Part 11, and EU Annex 11, alongside ISO 27001 certification. Its audit trails, role-based access controls, and controlled study changes are relevant to evaluating data integrity and inspection readiness under MHRA GCP expectations.
Considerations
Confirm deployment-specific validation evidence, UK GDPR data-processing arrangements, hosting locations, and the scope of AI capabilities included.
Pricing: Available on request.
What Clinion EDC Users Say
G2 Rating: 4.6/5 | Read Clinion EDC Reviews on G2
2. Viedoc
Viedoc offers configurable electronic data capture through Viedoc Designer, enabling study teams to build eCRFs, edit checks, and reusable study components. Its versioning model supports multiple concurrent study designs and amendments without traditional data migration or downtime.
Viedoc also provides data review, query management, and reporting tools, alongside ePRO/eCOA and randomisation capabilities.
Key features
- Low-code study configuration with reusable libraries and optional JavaScript for complex logic.
- Concurrent study versions and controlled amendments without downtime.
- Data review workflows and an Inspection Readiness Packet for customers.
UK regulatory and data protection relevance
Viedoc documents audit trails, validation support, and security assurance measures. Its Inspection Readiness Packet provides supplier documentation that UK sponsors and CROs can assess during vendor qualification and MHRA inspection preparation.
Considerations
Complex configurations may require JavaScript. Confirm the hosting region, international data-transfer arrangements, and which AI features are currently available.
Pricing: Available on request.
What Viedoc Users Say
G2 Rating: 4.5/5 | Read Viedoc Reviews on G2
3. Medidata Rave EDC
Medidata Rave EDC supports enterprise clinical data management across large, multisite and multinational studies. Its capabilities include reusable study standards, configurable edit checks, protocol amendments, and integration with Medidata’s broader clinical trial technology ecosystem.
A major differentiator is Medidata Clinical Data Studio, which brings EDC and external clinical datasets together for reconciliation, anomaly detection, and AI-assisted data review.
Key features
- Enterprise study configuration, reusable standards, and controlled protocol amendments.
- Cross-source data review, reconciliation, and anomaly detection through Clinical Data Studio.
- Integration with eCOA, RTSM, imaging, and external clinical data sources.
UK regulatory and data protection relevance
Medidata publishes security and privacy assurance information, including ISO certifications and SOC 2 reporting. Its data review, auditability, and supplier quality documentation can support UK sponsors assessing system controls under ICH E6(R3) and MHRA GCP expectations.
Considerations
Implementation and administration may require specialist resources. Confirm the specific modules, validation documentation, hosting arrangements, and international transfer safeguards applicable to the proposed deployment.
Pricing: Available on request.
What Medidata Rave EDC Users Say
G2 Rating: 4.7/5 | Read Medidata Rave EDC Reviews on G2
4. Veeva Vault EDC
Veeva Vault EDC is a clinical data capture platform within Veeva’s broader Vault Clinical ecosystem. It supports study configuration, data review, and protocol amendments while connecting clinical data management with other Veeva applications.
A key differentiator is its integration with Veeva Data Query System (DQS) for reviewing data from EDC and external sources. Veeva also provides structured release-validation documentation, which can help sponsors assess system changes and maintain qualification records.
Key features
- Configurable study builds and protocol amendments without planned study downtime.
- Multi-source clinical data review through Veeva DQS.
- Integration with Vault Clinical applications and documented release-validation processes.
UK regulatory and data protection relevance
Veeva publishes validation materials, including installation and operational qualification protocols, validation impact assessments, and requirements documentation. These can support UK sponsors’ computerised system assessments and inspection preparation under MHRA GCP guidance.
Considerations
Veeva may offer the greatest operational benefit to organisations already using Vault applications. Buyers should confirm UK GDPR data-processing arrangements, hosting locations, and the availability of newer AI-assisted study-building features.
Pricing: Available on request.
What Veeva Vault Users Say
G2 Rating: 4.1/5 | Read Veeva Vault Reviews on G2
5. Castor EDC
Castor EDC provides electronic data capture alongside eConsent and eCOA capabilities. Its study-building tools allow research teams to configure forms, validation rules, and data collection workflows without extensive programming.
Castor stands out for its documented UK data-hosting option and Castor Catalyst, which uses AI to extract clinical information from electronic health records and source documents, with human verification built into the workflow.
Key features
- User-friendly study configuration, electronic forms, and automated validation checks.
- Castor Catalyst for AI-assisted extraction of clinical source data.
- Integrated eConsent and eCOA, with API-based data exchange capabilities.
UK regulatory and data protection relevance
Castor documents audit trails, validation controls, and a UK hosting option. This gives UK sponsors a specific data-residency arrangement to assess during procurement, although UK GDPR compliance also depends on processing agreements, subprocessors, and international data transfers.
Considerations
Confirm which products and services can be hosted in the UK, as AI processing and connected services may use different infrastructure. Buyers should also review validation documentation and integration requirements.
Pricing: Available on request.
What Castor EDC Users Say
G2 Rating: 4.6/5 | Read Castor Reviews on G2
6. Medrio EDC
Medrio EDC is designed to simplify clinical study setup and data management, particularly for teams seeking greater control over configuration without relying heavily on specialist programmers.
Its point-and-click study builder supports reusable templates, edit checks, and self-service changes. An always-available testing environment allows teams to assess updates before deploying them to live studies. Medrio also offers connected eCOA, eConsent, and RTSM capabilities.
Key features
- No-code study configuration with reusable templates and validation rules.
- Persistent testing environment for reviewing study changes before release.
- Self-service amendments and integration with eCOA, eConsent, and RTSM.
UK regulatory and data protection relevance
Medrio’s testing environment and change-management workflows can help sponsors document study configuration and validation activities. Its audit trails and access controls are also relevant to data integrity assessments under ICH E6(R3) and MHRA GCP expectations.
Considerations
Buyers should verify available hosting regions, UK GDPR transfer safeguards, and the extent of integration between selected modules. Planned AI connectivity features should not be treated as currently available functionality without confirmation.
Pricing: Available on request.
What Medrio EDC Users Say
G2 Rating: 4.2/5 | Read Medrio EDC Reviews on G2
7. Oracle Clinical One
Oracle Clinical One is an enterprise clinical trial platform combining electronic data capture with randomisation, trial supply management, and connected clinical data workflows. It is particularly relevant to studies requiring coordinated data collection and investigational product management.
Its Advanced Study Versioning functionality allows teams to manage study updates through defined draft, testing, approval, and production stages. Oracle also provides release documentation to help customers evaluate platform updates.
Key features
- Advanced Study Versioning for controlled amendments during active trials.
- Integrated EDC, randomisation, and trial supply management.
- Connections with external clinical systems and structured release documentation.
UK regulatory and data protection relevance
Oracle provides Product Verification Packs and release assessment materials that can support system qualification and change-control documentation. These are useful for UK sponsors evaluating computerised systems against MHRA inspection expectations and ICH E6(R3) principles.
Considerations
Implementation may be more involved where multiple Oracle modules or external systems are required. UK buyers should verify deployment-specific validation evidence, data-hosting arrangements, international transfers, and any dependencies between study amendments and connected systems.
Pricing: Available on request.
What Oracle Clinical Users Say
G2 Rating: 4.1/5 | Read Oracle Clinical Reviews on G2
How to Choose the Right EDC Software for UK Clinical Trials
Choosing an EDC platform requires more than comparing features. UK sponsors and CROs should assess how well a system supports their study design, regulatory responsibilities, data protection requirements, and day-to-day clinical data management.
The following six factors are particularly important when evaluating EDC software in 2026.
1. MHRA Requirements and ICH E6(R3) Alignment
The updated UK Clinical Trials Regulations, effective from 28 April 2026, reinforce risk-proportionate quality management and appropriate oversight of clinical trial activities.
When evaluating an EDC platform, assess whether it provides:
- Complete, attributable audit trails and reliable electronic records.
- Role-based access controls and documented user permissions.
- Evidence of system validation, testing, and change control.
- Data review workflows that support risk-based oversight.
- Accessible records and documentation for MHRA inspections.
Vendors may also reference FDA 21 CFR Part 11 or EU Annex 11. These can provide useful evidence of electronic-record controls, but neither should be treated as a substitute for UK-specific regulatory assessment.
2. UK GDPR, Data Hosting, and Security
Clinical trial platforms frequently process health information, which receives additional protection under UK GDPR.
Evaluate where participant data is stored, who can access it, which subprocessors are involved, and whether data is transferred internationally. UK-only hosting is not a universal GDPR requirement, but international transfers must have an appropriate legal basis and safeguards.
Review the vendor’s:
- Data Processing Agreement (DPA) and subprocessor arrangements.
- Hosting, backup, disaster recovery, and data access locations.
- Encryption, pseudonymisation, and access controls.
- International transfer mechanisms, where applicable.
The ICO’s guidance on international transfers provides further information on these obligations.
3. Study Configuration and Protocol Amendments
Study requirements can change after enrolment begins. The EDC should support amendments without creating unnecessary disruption or compromising existing data.
Look for reusable eCRF libraries, configurable edit checks, version control, documented testing, and clear procedures for deploying changes to live studies.
Ask vendors to demonstrate an actual protocol amendment rather than relying solely on claims about flexible study configuration.
4. Data Review, AI, and Clinical Data Quality
Modern EDC platforms increasingly offer AI-assisted data review, anomaly detection, medical coding, and reporting. However, the availability and maturity of these capabilities differ significantly.
Assess whether the platform can identify discrepancies, prioritise review activities, generate queries, and produce custom reports. For AI functionality, establish what is automated, what requires human approval, and whether outputs remain traceable and auditable.
The priority should be measurable improvements to clinical data workflows, not the number of AI features advertised.
5. Integration With Other Clinical Trial Systems
An EDC rarely operates independently. UK studies may require integration with RTSM, CTMS, ePRO/eCOA, eConsent, central laboratories, imaging systems, or external clinical data sources.
Check whether integrations are native, API-based, or dependent on third-party services. Also review how the platform handles data corrections, reconciliation, system failures, and changes to connected workflows.
6. Implementation, Support, and Long-Term Costs
The initial software price is only one part of the investment. Sponsors should understand the resources needed for study setup, training, validation, amendments, support, and data archiving.
Under the amended UK regulations, applicable essential trial records may need to be retained for at least 25 years after trial conclusion, subject to the relevant rules and transitional arrangements. EDC buyers should therefore confirm long-term data access, export formats, audit-trail preservation, and archiving responsibilities.
Questions to Ask EDC Vendors Before Making a Decision
A product demonstration should show how the platform handles real study workflows, not simply showcase individual features.
Practical tip: Give shortlisted vendors the same study scenario and compare their demonstrations using a consistent evaluation checklist.
Finding the Right EDC Software for Your UK Clinical Trial
There is no single EDC platform that fits every clinical trial. The right choice depends on study complexity, the capabilities of your clinical data management team, and how well the software supports your existing workflows.
The seven platforms reviewed offer different strengths, from flexible study configuration and enterprise data management to AI-assisted review and integrated clinical trial operations. For UK sponsors and CROs, the priority is to select a platform that meets their operational needs while supporting data integrity, regulatory oversight, and long-term study requirements.
If reducing manual effort and bringing clinical trial workflow together are priorities, Clinion EDC is worth evaluating. Its codeless study builder, AI-assisted data management, and well-connected ecosystem help teams manage clinical data with greater efficiency.
Why Clinion EDC Is the Best Choice for UK Clinical Trials
For UK sponsors and CROs, the right EDC platform must support efficient clinical data management while meeting expectations around data integrity, system validation, and regulatory oversight. Clinion EDC combines codeless study configuration, AI-assisted discrepancy detection, medical coding, and natural-language reporting with audit trails, role-based access controls, and controlled protocol amendments. These capabilities support evaluation against MHRA GCP expectations and ICH E6(R3), while Clinion’s connected eClinical ecosystem helps streamline workflows across EDC, CTMS, RTSM, ePRO, eConsent, and eSource.
With experience spanning 650+ clinical trials across 20+ countries, Clinion combines an established track record with AI-driven capabilities. Its reported 80–90% faster report generation and zero study downtime during protocol updates offer practical advantages for teams managing data-intensive, multisite, and international clinical trials.
Request a Clinion EDC Demo to explore how Clinion can support efficient, inspection-ready clinical data management for your UK studies.
— FAQ's
Frequently Asked Questions About EDC Software for UK Clinical Trials
The best choice depends on trial complexity, study size, internal resources, and integration requirements. Clinion is worth considering for AI-powered, integrated clinical data management; Viedoc for flexible protocol amendments; Medidata Rave and Oracle Clinical One for complex enterprise trials; Veeva for organisations using Vault applications; Castor for source-data workflows and a documented UK hosting option; and Medrio for self-service study configuration.
There is no general MHRA certification that automatically makes an EDC platform suitable for every UK clinical trial. Sponsors must assess whether the selected system is fit for its intended purpose and whether appropriate validation, data integrity, security, and oversight controls are in place.
No. UK GDPR does not universally require clinical trial data to remain within the UK. However, organisations must meet applicable data protection obligations, including appropriate arrangements for restricted international transfers. Hosting location, remote access, subprocessors, and AI processing should all be evaluated.
Not by itself. FDA 21 CFR Part 11 addresses electronic records and signatures within its US regulatory scope. For UK trials, sponsors must assess the applicable UK Clinical Trials Regulations, MHRA guidance, ICH GCP expectations, and UK data protection requirements. Part 11 controls may support that assessment but do not replace it.
Yes. AI can assist with discrepancy detection, data review, coding, and reporting, provided its use is appropriately controlled and fit for purpose. Sponsors should understand how outputs are generated, validated, reviewed, and documented, with qualified personnel retaining responsibility for clinical decisions and data quality.
Before migration, confirm how clinical data, metadata, audit trails, queries, and other relevant records will be transferred and verified. Sponsors should also review system validation, continuity of ongoing study activities, integration dependencies, user training, and long-term access to historical records.
Unlock the Future of Clinical Trials with Clinion.
Cut your trial costs by 35% and accelerate your time-to-market by 30%